Heat Biologics, Inc. (HTBX) ended last trading session with a change of 7.79 percent. It trades at an average volume of 1.21M shares versus 11.41M shares recorded at the end of last trading session. The share price of $0.97 is at a distance of 142.52 percent from its 52-week low and down -71.04 percent versus its peak. The company has a market cap of $26.19M and currently has 27M shares outstanding. The share price is currently 9.86 percent versus its SMA20, 6.11 percent versus its SMA50, and -11.67 percent versus its SMA200. The stock has a weekly performance of 15.49 percent and is 12.8 percent year-to-date as of the recent close.
On March 13, 2017 Heat Biologics, Inc. (HTBX) announced that the company achieved the efficacy endpoint for its Phase 1b trial evaluating HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®), for the treatment of non-small cell lung cancer (NSCLC) and that the trial met the expansion criteria to advance into a Phase 2. In reviewing the Phase 1b data, the Data Monitoring Committee (DMC) determined that the Phase 1b safety endpoint was met and that there do not appear to be additional toxicities seen in the HS-110/nivolumab combination compared to existing data on nivolumab alone. Furthermore, 5 out of 15 patients treated with the HS-110/nivolumab combination had 20% or greater tumor reduction. The DMC concluded that the positive safety profile, mechanistic evidence and encouraging signs of synergistic efficacy warranted expansion to a Phase 2 trial.
Gilead Sciences, Inc. (GILD) recently recorded -0.13 percent change and currently at $68.1 is 4.16 percent away from its 52-week low and down -32.74 percent versus its peak. It has a past 5-day performance of -2.88 percent and trades at an average volume of 10.77M shares. The stock has a 1-month performance of 3.83 percent and is -4.9 percent year-to-date as of the recent close. There were about 1.31B shares outstanding which made its market cap $89.27B. The share price is currently -1.79 percent versus its SMA20, -4.29 percent versus its SMA50, and -10.97 percent versus its SMA200.
On February 15, 2017 Gilead Sciences, Inc. (GILD) announced 144-week data from two Phase 3 studies (Studies 104 and 111) evaluating the safety and efficacy of Genvoya® (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg) for the treatment of HIV-1 infection in treatment-naïve adults. Through Week 144, Genvoya demonstrated significantly higher rates of virologic suppression compared to Gilead’s Stribild® (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg), based on the percentage of patients with HIV-1 RNA levels less than 50 copies/mL. Patients receiving Genvoya also demonstrated favorable renal and bone laboratory parameters compared to those treated with Stribild. The data were presented in a poster session (Poster 0393) at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.